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Background: Genomic testing to identify driver mutations that 
enable targeted therapy is emerging for patients with non–small-cell 
lung cancer (NSCLC). We report the implementation of systematic 
prospective genotyping for somatic alterations in BRAF, PIK3CA, 
HER2, and ALK, in addition to EGFR and KRAS, in NSCLC patients 
at the Dana-Farber Cancer Institute.
Methods: Patients with NSCLC were prospectively referred by their 
providers for clinical genotyping. Formalin-fixed, paraffin embedded 
tumor samples were analyzed by Sanger sequencing for mutations in 
selected exons of EGFR, KRAS, BRAF, PIK3CA, and HER2. ALK 
rearrangements were detected by fluorescence in situ hybridization 
or immunohistochemistry.
Results: Between July 1, 2009 and August 1, 2010, 427 specimens 
from 419 patients were referred for genomic characterization; 344 
(81%) specimens were successfully genotyped with a median turn-
around time of 31 days (range, 9–155). Of the 344 specimens, 185 
(54%) had at least one identifiable somatic alteration (KRAS: 24%, 
EGFR: 17%, ALK: 5%, BRAF: 5%, HER2: 4%, PIK3CA: 2%). As 
of August 1, 2011, 63 of 288 advanced NSCLC patients (22%) 
had received molecularly targeted therapy based on their genotypic 
results, including 34 of 42 patients (81%) with EGFR mutations, 12 
of 15 (80%) with ALK rearrangements, and 17 of 95 (18%) with 
KRAS, BRAF, or HER2 mutations.
Conclusions: Large-scale testing for somatic alterations in EGFR, 
KRAS, BRAF, PIK3CA, HER2, and ALK is feasible and impacts 
therapeutic decisions. As the repertoire for personalized therapies 
expands in lung cancer and other malignancies, there is a need to 
develop new genomics technologies that can generate a comprehen-
sive genetic profile of tumor specimens in a time- and cost-effective 
manner.
Key Words: Lung cancer, Cancer genomics, Molecular targeted 
therapy.
(J Thorac Oncol. 2012;7: 1767–1774)
Targeted cancer therapy is transforming the care of patients with non–small-cell lung cancer (NSCLC) and driving 
efforts to incorporate tumor genotyping into clinical decision-
making. For example, it is now standard care to examine tumor 
specimens from patients with NSCLC for somatic alterations 
in EGFR to identify those with sensitizing mutations for initial 
therapy with gefitinib or erlotinib.1 Similarly, the anaplastic 
lymphoma kinase (ALK) tyrosine kinase inhibitor, crizotinib, 
has shown response rates in excess of 60%, progression-free 
survival greater than 10 months, and median survival in excess 
of 2 years from the start of crizotinib therapy in patients with 
advanced NSCLC bearing ALK rearrangements.2,3 Crizotinib 
is recommended as initial therapy for ALK-rearranged NSCLC 
in the National Comprehensive Cancer Network guidelines.
Thus far, approximately 15% to 20% of NSCLC 
patients from Europe and North America have tumors bearing 
EGFR mutations or ALK rearrangements, with drugs avail-
able to treat these genomic changes. Other potential therapeu-
tic targets emerging in 2009 in patients with NSCLC included 
activating mutations in KRAS, BRAF, HER2, and PIK3CA. 
KRAS is the RAS family member most frequently mutated in 
lung adenocarcinomas, with mutations in codons 12, 13, and 
61 detected in approximately 20% of cases. KRAS mutations 
are a negative predictive marker for response to epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors, 
and a potential therapeutic target.4 Activating mutations in 
BRAF, HER2, and PIK3CA have each been reported at lower 
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frequencies in NSCLC, ranging from 1% to 3%.5–8 Ongoing 
research at our institution and others is attempting to deter-
mine whether therapeutic inhibition of KRAS, BRAF, HER2, 
and PIK3CA will be an effective strategy in NSCLC, and to 
identify additional driver mutations that can be successfully 
targeted with existing or novel compounds. Therefore, consis-
tent multiplex genotyping is needed for patients with NSCLC 
to inform therapeutic choices and to expand the possible can-
didates for personalized lung cancer therapies.
The Lowe Center for Thoracic Oncology at the Dana-
Farber Cancer Institute, in conjunction with the Center for 
Advanced Molecular Diagnostics in the Pathology Department 
at the Brigham and Women’s Hospital and the Laboratory for 
Molecular Medicine at the Partners Healthcare Center for 
Personalized Genetic Medicine, introduced prospective geno-
typing of advanced NSCLC for somatic alterations in BRAF, 
HER2, PIK3CA, and ALK in July 2009, in addition to routine 
mutational analysis of EGFR and KRAS, which had been ongo-
ing since 2004. Three years have passed since we initiated this 
expanded genomic testing, allowing adequate time for deter-
mining the success of genomic characterization and assigning 
patients to therapies based on the molecular findings. The pur-
pose of this report is to provide data on the ability of our center 
to generate this information and to guide other institutions as 
they develop and modify their procedures for multiplex genomic 
characterization of lung cancers and other solid tumors.
MATERIALS AND METHODS
Study Population
Patients eligible for this analysis included those with 
histologically or cytologically confirmed NSCLC who under-
went genomic characterization of BRAF, PIK3CA, and HER2 
when added to the ongoing standard characterization of EGFR 
and KRAS, from July 1, 2009 until August 1, 2010. Specific 
genotyping studies were ordered at the discretion of the treat-
ing provider; in a majority of cases, ALK testing was also per-
formed. Patients could be genotyped anytime during the course 
of their therapy. Patients were identified through a query of 
patient information for subjects prospectively enrolled in the 
Clinical Research Information System in the Lowe Center for 
Thoracic Oncology at the Dana-Farber Cancer Institute, which 
tracks all the patients referred for genomic testing from our 
center. This patient information has been used for previous 
reports.9–11 Patients studied during a period of 13 months were 
evaluated to include a full year of data, including those dur-
ing the first month start-up phase. Patients whose tumors were 
tested after August 1, 2010 were excluded from this analy-
sis to assure at least 1 year of clinical follow-up after testing. 
During the study period, EGFR and KRAS tumor genotyping 
were considered routine clinical tests without the need for 
patient consent. Patients provided written informed consent 
for BRAF, PIK3CA, HER2, and ALK testing, as well as for 
the collection of baseline information, details on their treat-
ments, clinical outcomes information, and for contacting them 
for potential trials. The collection of clinical information on 
patients referred for genotyping was approved by the local 
institutional review board at the Dana-Farber Cancer Institute.
Genomic Characterization
Tumor specimens submitted for genomic characteriza-
tion consisted of formalin-fixed paraffin-embedded (FFPE) 
material and were prescreened by a board-certified patholo-
gist (NIL) to confirm adequate tumor material for test-
ing. Specimens were analyzed for the presence of somatic 
mutations of EGFR (exons 18–21), KRAS (exons 2 and 3), 
BRAF (exons 11 and 15), PIK3CA (exons 8, 10, and 21), and 
HER2 (exon 20) by bidirectional Sanger dideoxyterminator 
sequencing according to described methods.12 This method 
allows detection of expected key driver mutations in the 
genes tested as well as other genetic changes that may have 
clinical significance. Mutation analysis was performed at the 
Laboratory for Molecular Medicine at the Partners Healthcare 
Center for Personalized Genetic Medicine under conditions 
certified according to the Clinical Laboratory Improvement 
Amendments. Only mutations detected on both forward and 
reverse strands and confirmed by testing a second aliquot of 
DNA were reported as positive. Sequences were indepen-
dently interpreted by two technologists, a molecular geneticist 
(VAJ) and a pathologist (NIL).
Fluorescence in situ hybridization (FISH) was per-
formed on 4-micron sections of FFPE tumor samples cut 
onto glass slides, using an ALK break-apart probe (Abbott 
Vysis, Abbott Park, IL), according to previously described 
methods.2,3 FISH-positive specimens were defined as sepa-
rated orange and green signals, with a split distance of at least 
2 probe diameters, in more than 15% of tumor cells. FISH 
slides were independently interpreted by two technologists, a 
cytogeneticist (VAJ), and a pathologist(NIL). In some cases, 
immunohistochemistry was initially performed, and samples 
scored as positive or equivocal for ALK expression were con-
firmed by FISH analysis, as previously reported.13 Before the 
laboratory became more efficient at handling high throughput, 
a number of samples were referred to a commercial labora-
tory for ALK FISH testing. Other samples were prospectively 
assessed for ALK rearrangements at a central laboratory as 
part of eligibility screening for clinical trials.
Statistical Methods
Baseline clinical characteristics were determined 
by prospective collection from a patient-administered 
questionnaire. Smoking status was categorized as never (<100 
lifetime cigarettes), light (≤10 pack-years) or heavy smoker 
(>10 pack-years). Tumor histology was classified using the 
2004 World Health Organization criteria.14
Patients who had a somatic alteration in at least one 
of the six genes were categorized as being treated with a 
molecularly targeted therapy if they received an agent tar-
geted against that genomic change or closely related down-
stream pathway. Patients were also considered to have been 
assigned to a molecularly targeted therapy if they partici-
pated in a trial where prospective identification of a muta-
tion was required for enrollment. For instance, the patients 
with KRAS mutations who were entered on the trial where 
they were assigned either to docetaxel or docetaxel plus 
selumetinib were categorized as being treated with targeted 
therapy (NCT00890825).
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Summary statistics are provided regarding the demo-
graphic and disease characteristics of the 419 patients tested 
and are summarized by mutation status. Wilcoxon rank sum 
and Fisher’s exact tests were used to compare the character-
istics between patients with genomic changes and wild-type 
tumors. Turnaround time was calculated as the interval from 
the time of test requisition until genotyping report finaliza-
tion and included the time required to obtain the FFPE tumor 
material, which had to be requested from outside hospitals 
in some cases; to section and review the submitted material 
for adequacy; to extract, amplify, and sequence DNA, and 
to re-extract DNA in the case of inadequate malignant tissue 
amount or integrity in the original tested sample; to transport 
the sample to and from the laboratory with genomic charac-
terization capability; and to interpret and sign out the results. 
The turnaround time was calculated for BRAF, HER2, and 
PIK3CA mutational analysis; specimens were most frequently 
also tested for mutations in EGFR and KRAS, although in some 
cases, mutational analysis of EGFR and KRAS had previously 
been performed. The turnaround time could not be reliably 
assessed for specimens referred for ALK testing as different 
laboratories were involved. All reported p values were based 
on two-sided hypothesis tests. The statistical analysis was per-
formed using SAS 9.2.
RESULTS
Patient Characteristics
Between July 1, 2009 and August 1, 2010, 427 specimens 
from 419 patients with NSCLC were prospectively referred 
for clinical genotyping for mutations in BRAF, PIK3CA, 
and HER2. Table 1 shows the demographic and clinical 
characteristics of these 419 patients. The median age of the 
study cohort was 61 years (range, 24–95). There were 173 
men (41%) and 246 women (59%) , and 36% of the patients 
were never or light smokers (≤10 pack-years). Most patients 
were white, non-Hispanic, reflecting the predominant ethnic 
background of our clinic population. The majority of patients 
(80%) had stage IV or relapsed NSCLC at the time of genetic 
test requisition . Histology was predominantly adenocarcinoma 
(87%), reflecting the patient population primarily targeted by 
clinical genotyping at our institution. Eight patients had two 
different samples tested; four of these patients had a second 
specimen submitted because the original sample contained 
insufficient tumor material for genetic analysis, two patients 
had samples from two different body sites tested, and two 
patients underwent surgical resection of synchronous primary 
tumors and each tumor was successfully genotyped.
Genomic Characterization
Of the 427 specimens referred for genomic charac-
terization of BRAF, HER2, and PIK3CA, 344 specimens 
(81%) from 341 patients were successfully tested. Table 
2 outlines the reasons for the 83 samples that did not com-
plete genetic analysis. Genotyping failures occurred more 
often in specimens obtained from bone (five of nine samples 
did not complete genetic analysis). Correspondingly, recent 
reports have shown that fixatives with a low pH, such as 
bone-decalcifying solutions, can affect the quality and quan-
tity of DNA in the samples, thereby interfering with molecular 
testing.15 Therefore, subsequent bone samples were excluded 
from this study and genomic testing on bone specimens is no 
TABLE 1.  Baseline Patient Characteristics
Total no. of patients 419
Median age, years (range) 61 (24–95)
Sex, no. (%)
Male 173 (41)
Female 246 (59)
Race, no. (%)
White, non-Hispanic 371 (89)
White, Hispanic 6 (1)
Asian 12 (3)
Black 28 (7)
Other 2 (<1)
Smoking status, no. (%)a
Never smoker 97 (23)
≤ 10 pack-yrs 55 (13)
> 10 pack-yrs 262 (63)
Histology, no. (%)
Adenocarcinoma 363 (87)
Adenosquamous 12 (3)
Squamous 7 (2)
Large cell carcinoma 4 (1)
NSCLC NOS 33 (8)
Stageb
I/II/IIIA 31 (7) / 14 (2) / 30 (7)
IIIB 9 (2)
IV 217 (52)
Relapsedc 118 (28)
aData not available for five patients.
bAmerican Joint Committee on Cancer staging system, 7th edition.
cPatients with stage I–IIIA NSCLC with relapse after definitive therapy.
NOS, not otherwise specified; NSCLC, non–small-cell lung cancer.
TABLE 2.  Specimens Referred for Clinical Genotyping
No. (%)
Specimens referred for BRAF, HER2, and PIKC3CA 
mutational analysis
427 (100)
Specimens that did not complete genetic analysis 83 (19)
Insufficient tumor material for genotyping; testing not 
performeda
34 (8)
Insufficient tumor material for conclusive results; 
testing performedb
22 (5)
Failed polymerase chain reaction amplification 15 (4)
Incomplete testing at all predefined exons of BRAF,  
HER2, and/or PIK3CA
6 (1)
Specimen could not be located 6 (1)
Specimens successfully tested for BRAF, HER2 and  
PIK3CA mutations
34 (81)
aInsufficient tumor material for genotyping identified during pathology prereview.
bTwenty-two specimens were found to be wild-type for BRAF, HER2, and PIK3CA but 
were classified as inconclusive because there was < 50% malignant tissue in the specimen.
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longer routinely performed at our center. Of the 344 samples 
successfully tested for BRAF, HER2, and PIK3CA mutations, 
336 samples (98%) were also successfully tested for EGFR 
mutations, 328 (95%) were successfully tested for mutations 
in KRAS, and 310 (90%) underwent successful ALK testing.
Among the 344 genotyped specimens, the median turn-
around time was 31 days (range, 9–155). The turnaround time 
was significantly longer when pathology specimens were 
obtained from outside institutions (n=138) compared with 
specimens available in the Department of Pathology at the 
Brigham and Women’s Hospital (n=206) (median 36 versus 28 
days, respectively; p < 0.001). Sixty-four specimens had a turn-
around time greater than 50 days, including three specimens 
with a turnaround time greater than 100 days. Of those three 
specimens, two required DNA re-extraction to meet quality 
standards, which significantly prolonged the turnaround time, 
and were subsequently successfully tested. The remaining spec-
imen was obtained from an outside hospital; 127 days elapsed 
before the tumor block was received, after which genomic test-
ing was successfully completed and reported in 28 days.
A somatic alteration in at least one of the six genes 
was identified in 185 of the 344 genotyped specimens (54%); 
seven of the 185 specimens harbored two mutations. Table 3 
lists the somatic mutations identified. Overall, we identified 
60 EGFR mutations in 56 of 336 specimens (17%) , 79 KRAS 
mutations in 79 of 328 specimens (24%), 16 BRAF mutations 
in 16 of 344 specimens (5%) , 15 HER2 mutations in 15 of 
344 specimens (4%) , and six PIK3CA mutations in six of 
344 specimens (2%). A rearrangement of the ALK gene was 
detected in 16 of the 310 successfully tested samples (5%) 
(FISH-positive: 12; immunohistochemistry-only positive: 
four). Three specimens harbored concurrent mutations in 
PIK3CA and either KRAS (n=2) or EGFR (n=1). Two speci-
mens with EGFR T790M had concurrent sensitizing EGFR 
mutations in exon 19. Two additional specimens harbored two 
EGFR mutations involving G719. Two novel BRAF mutations 
not previously reported in NSCLC patients were identified. 
BRAF p.1794_1796dupTAC (c.T599_V600insT), a somatic 
change previously described in a female patient with pancre-
atic cancer, was identified in one sample.16 Another specimen 
harbored BRAF p.1405_1407delGGA (c.G469del), a somatic 
change not previously reported in the literature; other mis-
sense mutations in BRAF codon 469 have been detected in 
solid tumors. One hundred and twenty-eight of 313 specimens 
(41%) were wild type at all predefined exons and negative for 
the ALK rearrangement.
The demographic and clinical characteristics of the 
patients with tumors bearing an identifiable oncogenic driver 
mutation or pan-negative (wild-type) tumors are shown 
in Table 4. Consistent with previous reports, in this study 
patients with ALK-rearranged tumors were significantly 
younger than patients with wild-type tumors (p = 0.005).17 
Further comparative analyses showed that never- or light-
smoking history (≤10 pack-years) was significantly associated 
with mutations in EGFR (p < 0.1001), BRAF (p = 0.073), 
PIK3CA (p = 0.048), and HER2 (p < 0.001), as well as ALK 
rearrangements (p < 0.001), although heavier smoking was 
significantly correlated with KRAS mutations (p = 0.007). 
The two patients with tumors bearing concurrent mutations 
in PIK3CA and KRAS were a 30-year-old white female never 
smoker with adenocarcinoma and a 58-year-old white male 
former heavy smoker with adenosquamous carcinoma. An 
81-year-old white female never smoker, had adenocarcinoma 
that harbored an EGFR exon 19 deletion and a PIK3CA 
mutation before exposure to any systemic therapy.
TABLE 3.  Somatic Gene Alterations Identified
Gene Exon Mutations Identified, No. (%)
EGFRa 60 (100)b
18 G719A: 2 (3); G719C: 1 (2); G719S: 1 (2)
19 Deletions: 13 (22); deletion-insertions: 8 (13)
L747P (cis) or L747L/L747S (trans)c: 2 (3)
20 Duplications: 4 (7); insertions: 2 (3); deletion-
insertions: 1 (2); deletions: 1 (2)
T790M: 2 (3); S768I: 1 (2)
21 L858R: 20 (33); L861Q: 2 (3)
KRASa 79 (100)d
2 G12C: 30 (38); G12D: 18 (23); G12V: 11 (14); 
G12A: 7 (9); G12S: 3 (4)
G12F (cis) or G12C/G12V (trans)e: 1 (1); G12L (cis) 
or G12R/G12V (trans) f: 1 (1)
G13C: 1 (1); G13D: 1 (1)
3 Q61H: 4 (5); Q61K: 1 (1)
BRAF 16 (100)
11 G466V: 1 (6); G466R: 1 (6); G469A: 1 (6); G469del: 
1 (6)
15 V600E: 9 (56); D594N: 1 (6); D594G: 1 (6)
T599_V600insT: 1 (6)
HER2 15 (100)
20 Duplications: 9 (60); insertions: 3 (20): deletion-
insertions: 2 (13)
V777L: 1 (7)
PIK3CAa 6 (100)
8 E453_P458delinsD: 1 (17)
10 E542K: 3 (50)
21 H1047R: 2 (33)
ALK 16 (100)
Rearrangement: FISH-positive, 12 (75); IHC-only 
positive, 4 (25)
aThree specimens harbored concurrent mutations in PIK3CA and either KRAS 
(n=2) or EGFR (n=1).
bFour specimens had two concurrent EGFR mutations.
cTwo specimens had two DNA sequence variants in EGFR: 2239T>C and 
2240T>C. If these two variants occur on the same allele (cis), the expected amino acid 
change is L747P. If these two variants occur on separate alleles (trans), the expected 
amino acid changes are L747L and L747S.
dOne specimen was tested at an outside facility and reported as positive for a KRAS 
mutation but information on the specific amino acid change was not available.
eTwo DNA sequence variants were detected in KRAS: 34G>T and 35G>T. If these 
variants occur on the same allele, the expected amino acid change is G12F. If these 
variants occur on separate alleles, the expected amino acid changes are G12C and 
G12V.
fTwo DNA sequence variants were detected in KRAS: 34G>C and 35G>T. If these 
variants occur on the same allele, the expected amino acid change is G12L. If these 
variants occur on separate alleles, the expected amino acid changes are G12R and 
G12V.
IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
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Clinical and Therapeutic Implications
As of August 1, 2011, 288 of the 341 patients (84%) 
were diagnosed with stage IV or relapsed metastatic NSCLC. 
Of the 288 patients, 152 (53%) had at least one identifiable 
somatic alteration (EGFR: 41, EGFR + PIK3CA: one, KRAS: 
62, KRAS + PIK3CA: two, BRAF: 15, HER2: 13, PIK3CA: 
three, ALK: 15). Thirty-five of the 152 patients (23%) enrolled 
in a study of molecularly targeted therapy, including nine of 
42 patients with EGFR mutations. An additional 25 EGFR 
mutant advanced NSCLC patients were treated with erlo-
tinib off protocol. Eight patients with EGFR mutations were 
not treated with an EGFR tyrosine kinase inhibitor. Of those 
eight patients, two were treated at outside institutions with no 
therapeutic information available; three had exon 20 insertion 
mutations, which were not sensitive to treatment with erlotinib 
or gefitinib; two were asymptomatic, requiring no systemic 
therapy for their advanced NSCLC; and one died shortly after 
the identification of a sensitizing mutation of EGFR. Twelve of 
15 patients with ALK-rearranged advanced NSCLC enrolled 
in a clinical trial, including two patients who were treated at 
outside institutions. Three patients with ALK rearrangements 
were not treated with crizotinib. Of the three patients, one 
remained on maintenance pemetrexed with prolonged stable 
disease at the time of this analysis; the remaining two patients 
were not eligible for trial enrollment because of poor perfor-
mance status and died shortly after the identification of an 
ALK rearrangement. Finally, three patients with HER2 muta-
tions received a trastuzumab-containing regimen off protocol. 
Thus, a total of 63 of 152 patients (41%) received molecularly 
tailored therapy based on their genetic alterations (Fig. 1).
Finally, one patient in our cohort had profiling of meta-
chronous resected bilateral T2 tumors that revealed two dis-
tinct genotypes (KRAS G12C in one case, and wild-type for all 
tested sites in the other), suggesting two early-stage primary 
tumors as opposed to metastatic disease. Another patient had 
a similar scenario, but the two specimens were wild type for 
all tested sites.
DISCUSSION
Over the past two decades, modifications of chemo-
therapy combinations and the addition of the antiangiogenic 
agent, bevacizumab, have brought about modest gains in sur-
vival for patients with advanced NSCLC.18–21 Treatment with 
erlotinib or gefitinib for NSCLC patients with EGFR muta-
tions and crizotinib for patients with ALK rearrangements 
has transformed therapy for these patient subsets. Other 
promising agents for lung cancers that harbor uncommon 
genomic changes are under development and have prompted 
the need for extensive genomic characterization of advanced 
NSCLC. Research efforts published in 2010 and 2011 per-
formed genetic profiling of resected NSCLC and defined the 
TABLE 4.  Demographics of the Patients Successfully Genotyped by Mutation Statusa
EGFRb KRASb ALK BRAF HER2 PIK3CAb Wild-Type
Proportion mutated (%) 55c/334 (16) 79/325 (24) 16/309 (5) 16/341 (5) 15/341 (4) 6/341 (2) 128/313 (41)
Median age (range) 58 (34–81) 63 (30–82) 54 (24–79) 61 (41–77) 61 (44–75) 66 (30–81) 63 (26–87)
Sex, no. (%)
Male 21 (38) 28 (35) 4 (25) 7 (44) 6 (40) 3 (50) 68 (53)
Female 34 (62) 51 (65) 12 (75) 9 (56) 9 (60) 3 (50) 60 (47)
Race, no. (%)
White, non-Hispanic 51 (93) 74 (94) 15 (94) 15 (94) 14 (93) 5 (83) 107 (84)
White, Hispanic 0 1 (1) 1 (6) 0 0 0 4 (3)
Asian 1 (2) 1 (1) 0 0 1 (7) 0 6 (5)
Black 3 (5) 2 (3) 0 1 (6) 0 1 (17) 10 (8)
Other 0 1 (1) 0 0 0 0 1 (1)
Smoking status, no. (%)d
Never-smoker 29 (53) 5 (6) 6 (38) 5 (31) 10 (67) 4 (67) 24 (19)
≤ 10 pack-yrs 12 (22) 3 (4) 6 (38) 3 (19) 4 (27) 0 8 (6)
≥ 10 pack-yrs 14 (25) 71 (90) 4 (25) 8 (50) 1 (7) 2 (33) 93 (73)
Histology, no. (%)
Adenocarcinoma 53 (96) 73 (92) 14 (88) 12 (75) 13 (87) 4 (67) 107 (84)
Adenosquamous 2 (4) 3 (4) 0 1 (6) 1 (7) 1 (17) 5 (4)
Squamous 0 0 0 0 0 0 3 (2)
Large-cell carcinoma 0 0 1 (6) 0 0 0 1 (1)
NSCLC NOS 0 3 (4) 1 (6) 3 (19) 1 (7) 1 (17) 12 (9)
aThree patients with two separate tumor specimens successfully genotyped were accounted for only once in the respective genotype cohort.
bThree patients had tumors bearing concurrent mutations in PIK3CA and either KRAS (n = 2) or EGFR (n = 1); the demographics of the patient corresponding with each of the 
three tumor specimens were included and accounted for in the respective genotype cohort.
cOne patient had samples from two different body sites tested, both of which showed an exon 20 insertion mutation of EGFR. The demographics of the patient were accounted for 
only once in the EGFR cohort.
dData not available for three patients in the wild-type cohort.
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frequency and types of somatic mutations of EGFR, KRAS, 
NRAS, HRAS, HER2, BRAF, PIK3CA, ALK rearrangements, 
and ROS1 fusions.12,22 Although resected lung cancers pro-
vide an abundant source of DNA for molecular profiling, the 
patients who more urgently need to undergo genomic char-
acterization are those with advanced or relapsed NSCLC to 
guide the selection of initial systemic therapy and to identify 
candidates for investigational therapy.
In the present study, we report our experience prospec-
tively screening 427 specimens from 419 patients for muta-
tions in BRAF, HER2, and PIK3CA, in addition to routine 
mutational analysis of EGFR and KRAS, during an initial 13 
months after implementation. In 90% of cases, ALK testing 
was also performed. Most specimens were successfully geno-
typed (344 of 427, 81%), and 185 of 344 specimens (54%) 
had an identifiable driver mutation. Drs. Dias-Santagata and 
Sequist1 previously reported on their ability to perform sys-
tematic genotyping of NSCLC. In their study, 552 of the 
589 patients (94%) referred for clinical genotyping had their 
tumors successfully genotyped. Notably, their population 
included a greater number of patients with resected stage I/
II NSCLC (197 of 546 or 37% versus 45 of 419 or 11% in 
our cohort), offering a potential explanation for the higher 
proportion of specimens that were successfully genotyped in 
their study. Likewise, their group used a genotyping technique 
called SNaPshot that requires smaller amounts of DNA and 
a less-pure population of tumor cells than the 50% malig-
nant cells needed for direct DNA sequencing used in this 
report.1,23 Correspondingly, we categorized 22 specimens that 
were found to be wild type at all predefined exons of BRAF, 
HER2 and PIK3CA as inconclusive because they contained 
less than 50% malignant cells. As routine lung cancer care is 
being redefined to incorporate tumor mutational profiling into 
clinical decision-making, the obstacles posed by limited tissue 
specimens stress the need to obtain adequate tumor material at 
the time of diagnostic sampling.
The goals of the genomic characterization of our 
NSCLC patients are to help guide therapy and ultimately lead 
to improved outcomes for those patients with specific genomic 
changes. Our group identified 152 of 288 patients (53%) with 
advanced or relapsed NSCLC with a somatic alteration of 
EGFR, KRAS, BRAF, PIK3CA, HER2, and/or ALK; 63 of the 
152 patients (41%) began a molecularly tailored therapy in 
response to genotypic results. We expect that this proportion 
should increase as the scope of genotype-specific clinical tri-
als is expanding at our institution and other centers. As was to 
be expected with proven effective therapies, the vast major-
ity of EGFR mutant advanced NSCLC patients were treated 
with erlotinib (34 of 42, 81%), either as part of a clinical trial 
or off protocol. Similarly, 12 of the 15 advanced NSCLC 
patients (80%) whose tumors harbored ALK rearrangements 
were treated with crizotinib. Research is ongoing to determine 
whether the outcomes of NSCLC patients with other genomic 
changes treated with targeted therapies are improved com-
pared with those given empiric chemotherapy.
An important issue is the length of time needed to perform 
multiplex diagnostic testing, which is critical for purposes of 
clinical decision making. In our study, the median turnaround 
time was 31 days (range, 9–155 ) for mutational analysis. 
This included the time required to obtain FFPE samples from 
FIGURE 1.  Flowchart of patients with 
stage IV or relapsed metastatic NSCLC onto 
molecularly targeted therapy during the 
study period. NSCLC, non–small-cell lung 
cancer
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outside hospitals in 40% of cases, and to transport specimens 
to and from the laboratory with genomic characterization 
capability for direct DNA sequencing. Other potential delays 
are technical. The Sanger sequencing assay involves mul-
tiple steps, including nested polymerase chain reaction, with 
quality-control assessments at several stages of the process. 
Turnaround times are also extended by our laboratory’s poli-
cies of confirming positive results with a second amplification 
from a second aliquot of DNA, and independent sequential 
interpretations by a total of four reviewers. Nevertheless, there 
is a strong desire to shorten the time needed to generate the 
genotypic information to rapidly implement appropriately tar-
geted therapy. The International Association for the Study of 
Lung Cancer—European Thoracic Oncology Platform mul-
tidisciplinary workshop recommended that EGFR mutation 
testing be completed within 7 working days.24 Similarly, draft 
recommendations by the College of American Pathologists in 
conjunction with the International Association for the Study 
of Lung Cancer and the Association for Molecular Pathology 
recommend that EGFR and ALK testing both be completed 
within 2 weeks (10 working days) of receiving the specimen 
in the testing laboratory. Therefore, retrieval and delivery 
of samples and testing in our center and others will need to 
take place more promptly. In September 2010, our molecular 
pathology laboratory introduced a rapid EGFR assay that pro-
vides genotype results for the two most common sensitizing 
mutations, exon 19 deletions and EGFR L858R, within 2 days 
(median) of receipt of the sample in the laboratory. This has 
led to a significant acceleration of the implementation of tar-
geted EGFR therapy. If this could be achieved for all molecu-
lar testing, it would be a major advance.
Similarly, there is a need for genotyping technology to 
evolve to generate a more comprehensive genetic analysis 
of routine clinical specimens, capturing point mutations, 
insertions, and deletions, as well as rearrangements and DNA 
copy number alterations in a single panel. This is especially 
relevant as we identify more nonmutational genomic targets 
in NSCLC, such as MET amplification, and ROS1 and RET 
rearrangements.25–27 Real-time prospective genotyping of 
NSCLC is currently challenged by the fact that different 
types of molecular alterations require different assays and 
necessitate tumor tissue to be processed properly in multiple 
ways. Moving forward, the adaptation of new technologies, 
such as next-generation sequencing, may offer a unifying 
approach to comprehensive profiling of tumor DNA, and 
potentially shorten the time of such analyses. Such targeted 
next-generation sequencing is clinically feasible and under 
development by commercial entities and academic centers.27
The primary limitations of our study are its retrospec-
tive observational design and the potential for selection bias 
introduced by the patients pursuing oncologic care at our ter-
tiary referral center and in whom providers requested clinical 
genotyping. Nevertheless, our genotyping results are consis-
tent with the documented mutational prevalence of the tested 
oncogenes.28 Similarly, although our findings support the 
clinical feasibility of broad prospective genotyping, the utility 
of this approach remains under investigation. Multiple agents 
targeting KRAS, BRAF, HER2, PIK3CA, and/or downstream 
pathways are in various phases of clinical development in 
patients with advanced NSCLC and prospectively identified 
mutations. These studies should help determine whether a tar-
geted therapeutic strategy will result in improved outcomes 
for these patients, analogous to those observed for NSCLC 
patients with EGFR mutations or ALK translocations.
In summary, our experience implementing systematic 
prospective genotyping for somatic alterations in EGFR, 
KRAS, ALK, BRAF, HER2, and PIK3CA demonstrates the 
feasibility of this approach within the clinical workflow. 
The genotypic information supported diagnostic decisions, 
directed the administration of available targeted therapeu-
tics, and facilitated enrollment of patients into clinical trials 
of molecularly tailored therapy. As the repertoire of muta-
tions for which targeted therapy may be offered expands in 
lung cancer and other solid malignancies, strategies to enable 
rapid, accurate and comprehensive clinical genotyping will 
be essential to successfully integrate tumor molecular analy-
sis into the fast pace of clinical decision making and yield its 
greatest potential impact on patient management.
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